Overseas Contractor Bill Could Give Pharma Federal Contracting Headaches In U.S.
This article was originally published in PharmAsia News
Executive Summary
A U.S. House-passed bill that would bar firms from federal contracts if they violate the Foreign Corrupt Practices Act could put any violative pharma firms at risk of losing participation in drug benefit programs with the Department of Veterans Affairs, Medicaid and Medicare
You may also be interested in...
Anti-Corruption, Compliance Scrutiny Increase In Emerging Markets
In the next few years, the Department of Justice's enforcement focus will be the Foreign Corrupt Practices Act and its application to the pharmaceutical industry, DoJ official says.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).